List of Tables
Table 1. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)
Table 5. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Nanomaterial-Based Adjuvants Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Nanomaterial-Based Adjuvants Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2021–2026
Table 18. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2027–2032
Table 20. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 27. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 32. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 33. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2021–2026
Table 37. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (M Doses), 2027–2032
Table 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 42. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 43. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2021–2026
Table 47. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (M Doses), 2027–2032
Table 48. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2021–2026)
Table 51. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2027–2032)
Table 52. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2021–2026)
Table 59. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2027–2032)
Table 60. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2021–2026)
Table 61. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2027–2032)
Table 62. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2021–2026)
Table 69. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2027–2032)
Table 70. Emergent BioSolutions Company Information
Table 71. Emergent BioSolutions Description and Business Overview
Table 72. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product
Table 74. Emergent BioSolutions Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Sanofi Nanomaterial-Based Adjuvants Vaccine Product
Table 79. Sanofi Recent Developments/Updates
Table 80. GlaxoSmithKline Biologicals Company Information
Table 81. GlaxoSmithKline Biologicals Description and Business Overview
Table 82. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product
Table 84. GlaxoSmithKline Biologicals Recent Developments/Updates
Table 85. Merck Company Information
Table 86. Merck Description and Business Overview
Table 87. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Merck Nanomaterial-Based Adjuvants Vaccine Product
Table 89. Merck Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Pfizer Nanomaterial-Based Adjuvants Vaccine Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Novartis Company Information
Table 96. Novartis Description and Business Overview
Table 97. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Novartis Nanomaterial-Based Adjuvants Vaccine Product
Table 99. Novartis Recent Developments/Updates
Table 100. Moderna Company Information
Table 101. Moderna Description and Business Overview
Table 102. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. Moderna Nanomaterial-Based Adjuvants Vaccine Product
Table 104. Moderna Recent Developments/Updates
Table 105. Jiangsu Recbio Technology Company Information
Table 106. Jiangsu Recbio Technology Description and Business Overview
Table 107. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product
Table 109. Jiangsu Recbio Technology Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Nanomaterial-Based Adjuvants Vaccine Distributors List
Table 113. Nanomaterial-Based Adjuvants Vaccine Customers List
Table 114. Nanomaterial-Based Adjuvants Vaccine Market Trends
Table 115. Nanomaterial-Based Adjuvants Vaccine Market Drivers
Table 116. Nanomaterial-Based Adjuvants Vaccine Market Challenges
Table 117. Nanomaterial-Based Adjuvants Vaccine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Nanomaterial-Based Adjuvants Vaccine
Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Type: 2025 & 2032
Figure 4. Aluminium Hydroxides Product Picture
Figure 5. Aluminium Phosphate Product Picture
Figure 6. Lipidosome Product Picture
Figure 7. Others Product Picture
Figure 8. Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Application: 2025 & 2032
Figure 10. Pneumococcus
Figure 11. Human Papilloma Virus
Figure 12. DTaP
Figure 13. Viral Hepatitis TypeA
Figure 14. Viral Hepatitis TypeB
Figure 15. SARS-CoV-2
Figure 16. Others
Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Market Size (US$ Million), 2021–2032
Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), 2021–2032
Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose), 2021–2032
Figure 21. Nanomaterial-Based Adjuvants Vaccine Report Years Considered
Figure 22. Nanomaterial-Based Adjuvants Vaccine Sales Share by Manufacturers in 2025
Figure 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers in 2025
Figure 24. Top 5 and Top 10 Global Nanomaterial-Based Adjuvants Vaccine Players: Market Share by Revenue in Nanomaterial-Based Adjuvants Vaccine in 2025
Figure 25. Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 27. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 29. United States Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Canada Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 32. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 33. Germany Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. France Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. U.K. Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Italy Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Russia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021–2032)
Figure 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021–2032)
Figure 40. China Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Japan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. South Korea Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. India Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Australia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. China Taiwan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Indonesia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Thailand Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Malaysia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Latin America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 50. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 51. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Argentina Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021–2032)
Figure 55. Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2021–2032)
Figure 56. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. UAE Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2021–2032)
Figure 60. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2021–2032)
Figure 61. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2021–2032)
Figure 62. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2021–2032)
Figure 63. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2021–2032)
Figure 64. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2021–2032)
Figure 65. Nanomaterial-Based Adjuvants Vaccine Value Chain
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
